Volume 23, Issue 3 (Iranian South Medical Journal 2020)
Iran South Med J 2020, 23(3): 236-247 |
Back to browse issues page
Raha Rahimikian1 
, Samad Akbarzadeh2 , Rahimeh Rahimi1 , Khalil Pourkhalili3 , Marzeah Mahmoodi4 , Ramin Seyedian5 , Khadejeh Ghasemi6 , Ali Movahed * 7
, Samad Akbarzadeh2 , Rahimeh Rahimi1 , Khalil Pourkhalili3 , Marzeah Mahmoodi4 , Ramin Seyedian5 , Khadejeh Ghasemi6 , Ali Movahed * 7
1- Department of Biochemistry, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
2- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Physiology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
4- Biological statistical group, School of Health, Bushehr University of Medical Sciences, Bushehr, Iran
5- Department of Pharmacology School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
6- Pediatric Department, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
7- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , amovahed58@gmail.com
2- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Physiology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
4- Biological statistical group, School of Health, Bushehr University of Medical Sciences, Bushehr, Iran
5- Department of Pharmacology School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
6- Pediatric Department, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
7- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , amovahed58@gmail.com
Abstract: (2653 Views)
Background: Individuals with diabetes mellitus are at serious risk of a wide range of cardiovascular complications. Urotensin 2 and its receptors play an important role in the development of cardiovascular diseeases through production of reactive oxygen species (ROS). Resveratrol is a polyphenol with antioxidant and anti-diabetic properties. The present study aimed to investigate the effects of resveratrol on urotensin 2 and its receptors in the heart tissues of diabetic rats.
Materials and Methods: In this experimental study, 48 male Wistar rats were divided into six groups (N= 8 in each group). Resveratrol was prepared in 0.5% carboxymethyl cellulose and given to the rats through oral gavage. At the end of the 60 days of treatment with resveratrol, rats’ heart tissue was collected.
Results: The weight of diabetic rats treated with 10 and 90 mg/kg bw of resveratrol significantly increased compared with the diabetic group. Furthermore, the serum levels of FBS, lipids, MDA, CK-MB and LDH decreased in the treated diabetic rats compared with the control group. Moreover, concentration of urotensin 2 and its receptors significantly decreased in the heart tissues of the diabetic rats treated with resveratrol at the dose of 10 mg/kg bw compared with the control group.
Conclusion: The current study indicated that resveratrol decreased FBS, lipids, weight, MDA and cardiac enzymes. Furthermore, resveratrol significantly reduced urotensin 2 and its receptors, which indicates its moderating effect on diabetes complications.
Materials and Methods: In this experimental study, 48 male Wistar rats were divided into six groups (N= 8 in each group). Resveratrol was prepared in 0.5% carboxymethyl cellulose and given to the rats through oral gavage. At the end of the 60 days of treatment with resveratrol, rats’ heart tissue was collected.
Results: The weight of diabetic rats treated with 10 and 90 mg/kg bw of resveratrol significantly increased compared with the diabetic group. Furthermore, the serum levels of FBS, lipids, MDA, CK-MB and LDH decreased in the treated diabetic rats compared with the control group. Moreover, concentration of urotensin 2 and its receptors significantly decreased in the heart tissues of the diabetic rats treated with resveratrol at the dose of 10 mg/kg bw compared with the control group.
Conclusion: The current study indicated that resveratrol decreased FBS, lipids, weight, MDA and cardiac enzymes. Furthermore, resveratrol significantly reduced urotensin 2 and its receptors, which indicates its moderating effect on diabetes complications.
Type of Study: Original |
Subject:
Biochemistry. Cell Biology and Genetics
Received: 2019/07/6 | Accepted: 2020/02/5 | Published: 2020/07/27
Received: 2019/07/6 | Accepted: 2020/02/5 | Published: 2020/07/27
References
1. Zameni F, Bakhtiyari M, Mansournia MA, et al. Is Incident Type 2 Diabetes Associated With Cumulative Excess Weight And Abdominal Adiposity? Tehran Lipid And Glucose Study. Diabetes Res Clin Pract 2018; 136: 134-42. [DOI:10.1016/j.diabres.2017.12.002]
2. Ogurtsova K, Da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global Estimates For The Prevalence Of Diabetes For 2015 And 2040. Diabetes Res Clin Prac 2017; 128: 40-50. [DOI:10.1016/j.diabres.2017.03.024]
3. Abdul-Ghani M, Defronzo RA, Del Prato S, et al. Cardiovascular Disease And Type 2 Diabetes: Has The Dawn Of A New Era Arrived? Diabetes Care 2017; 40(7): 813-20. [DOI:10.2337/dc16-2736]
4. Vaudry H, Leprince J, Chatenet D, et al. International :union: Of Basic And Clinical Pharmacology. XCII. Urotensin II, Urotensin II- Related Peptide, And Their Receptor: From Structure To Function. Pharmacol Rev 2015; 67(1): 214-58. [DOI:10.1124/pr.114.009480]
5. Liu JC, Chen CH, Chen JJ, et al. Urotensin II Induces Rat Cardiomyocyte Hypertrophy Via The Transient Oxidization Of Src Homology 2- Containing Tyrosine Phosphatase And Transactivation Of Epidermal Growth Factor Receptor. Mol Pharmacol 2009; 76(6): 1186-95. [DOI:10.1124/mol.109.058297]
6. Yoshimoto T, Matsushita M, Hirata Y. Role Of Urotensin II In Peripheral Tissue As An Autocrine/Paracrine Growth Factor. Peptides 2004; 25(10): 1775-81. [DOI:10.1016/j.peptides.2004.03.028]
7. Stirrat A, Gallagher M, Douglas SA, et al. Potent Vasodilator Responses To Human Urotensin-II In Human Pulmonary And Abdominal Resistance Arteries. Am J Physiol Heart Circ Physiol 2001; 280(2): H925-8. [DOI:10.1152/ajpheart.2001.280.2.H925]
8. Gruson D, Ginion A, Lause P, et al. Urotensin II And Urocortin Trigger The Expression Of Myostatin, A Negative Regulator Of Cardiac Growth, In Cardiomyocytes. Peptides 2012; 33(2): 351-3. [DOI:10.1016/j.peptides.2011.12.017]
9. Gruson D, Ginion A, Decroly N, et al. Urotensin II Induction Of Adult Cardiomyocytes Hypertrophy Involves The Akt/GSK-3β Signaling Pathway. Peptides 2010; 31(7): 1326-33. [DOI:10.1016/j.peptides.2010.04.009]
10. Djordjevic T, Belaiba RS, Bonello S, et al. Human Urotensin II Is A Novel Activator Of NADPH Oxidase In Human Pulmonary Artery Smooth Muscle Cells. Arterioscler Thromb Vasc Biol 2005; 25(3): 519-25. [DOI:10.1161/01.ATV.0000154279.98244.eb]
11. Libby P, Ridker PM, Hansson GK, et al. Inflammation In Atherosclerosis: From Pathophysiology To Practice. J Am Coll Cardiol 2009; 54(23): 2129-38. [DOI:10.1016/j.jacc.2009.09.009]
12. Watanabe T, Suguro T, Kanome T, et al. Human Urotensin II Accelerates Foam Cell Formation In Human Monocyte-Derived Macrophages. Hypertension 2005; 46(4): 738-44. [DOI:10.1161/01.HYP.0000184226.99196.b5]
13. Tsoukas P, Kane E, Giaid A. Potential Clinical Implications Of The Urotensin II Receptor Antagonists. Front Pharmacol 2011; 2: 38. [DOI:10.3389/fphar.2011.00038]
14. Liu Q, Wang S, Cai L. Diabetic Cardiomyopathy And Its Mechanisms: Role Of Oxidative Stress And Damage. J Diabetes Investig 2014; 5(6): 623-34. [DOI:10.1111/jdi.12250]
15. Roglic G. WHO Global Report On Diabetes: A Summary. Int J Noncommunicable Dis 2016; 1(1): 3-8. [DOI:10.4103/2468-8827.184853]
16. Rao MU, Sreenivasulu M, Chengaiah B, et al. Herbal Medicines For Diabetes Mellitus: A Review. Int J Pharmtech Res 2010; 2(3): 1883-92.
17. Ma DSL, Tan LT, Chan KG, et al. ResveratrolPotential Antibacterial Agent against Foodborne Pathogens. Front Pharmacol 2018; 9: 102. [DOI:10.3389/fphar.2018.00102]
18. Sadi G, Konat D. Resveratrol Regulates Oxidative Biomarkers And Antioxidant Enzymes In The Brain Of Streptozotocin-Induced Diabetic Rats. Pharm Biol 2016; 54(7): 1156-63.
19. Wang H, Yang YJ, Qian HY, et al. Resveratrol In Cardiovascular Disease: What Is Known From Current Research?. Heart Fail Rev 2012; 17(3): 437-48. [DOI:10.1007/s10741-011-9260-4]
20. Strunz CMC, Roggerio A, Cruz PL, et al. Down-Regulation Of Fibroblast Growth Factor 2 And Its Co-Receptors Heparan Sulfate Proteoglycans By Resveratrol Underlies The Improvement Of Cardiac Dysfunction In Experimental Diabetes. J Nutr Biochem 2017; 40: 219-27. [DOI:10.1016/j.jnutbio.2016.11.015]
21. Li G, Wang G, Shi J, et al. Trans-Resveratrol Ameliorates Anxiety-Like Behaviors And Fear Memory Deficits In A Rat Model Of PostTraumatic Stress Disorder. Neuropharmacology 2018; 133: 181-8. [DOI:10.1016/j.neuropharm.2017.12.035]
22. Su D, Wu S, Guo J, et al. Protective Effect Of Resveratrol Against Pseudorabies Virus-Induced Reproductive Failure In A Mouse Model. Food Sci Biotechnol 2016; 25(1): 103-6. [DOI:10.1007/s10068-016-0105-8]
23. Thomson M, Al-Amin ZM, Al-Qattan KK, et al. Anti-Diabetic And Hypolipidaemic Properties Of Garlic (Allium Sativum) In Streptozotocin-Induced Diabetic Rats. Int J Diabetes Metab 2007; 15: 108-15.
24. Guariguata L, Whiting DR, Hambleton I, et al. Global Estimates Of Diabetes Prevalence For 2013 And Projections For 2035. Diabetes Res Clin Pract 2014; 103(2): 137-49. [DOI:10.1016/j.diabres.2013.11.002]
25. Schoenfelder T, Cirimbelli TM, CitadiniZanette V. Acute Effect Of Trema Micrantha (Ulmaceae) On Serum Glucose Levels In Normal And Diabetic Rats. J Ethnopharmacol 2006; 107(3): 456-9. [DOI:10.1016/j.jep.2006.07.027]
26. Paiz RC, Juárez-Flores BI, Ortega C, et al. Glucose-Lowering Effect Of Xoconostle (Opuntia Joconostle A. Web., Cactaceae) In Diabetic Rats. J Med Plants Res 2010; 4(22): 2326-33.
27. Ng CS, Lee JY, Toh MP, et al. Cost-of-Illness Studies of Diabetes Mellitus: A Systematic Review. Diabetes Res Clin Pract 2014; 105(2): 151-63. [DOI:10.1016/j.diabres.2014.03.020]
28. Swanston-Flatt SK, Day C, Bailey CJ, et al. Traditional Plant Treatments For Diabetes. Studies In Normal And Streptozotocin Diabetic Mice. Diabetologia 1990; 33(8): 462-4. [DOI:10.1007/BF00405106]
29. Öztürk E, Arslan AKK, Yerer MB, et al. Resveratrol and Diabetes: A Critical Review Of Clinical Studies. Biomed Pharmacother 2017; 95: 230-4. [DOI:10.1016/j.biopha.2017.08.070]
30. Moridi H, Karimi J, Sheikh N, et al. Resveratrol-Dependent Down-Regulation Of Receptor For Advanced Glycation End-Products And Oxidative Stress In Kidney Of Rats With Diabetes. Int J Endocrinol Metab 2015; 13(2): e23542. [DOI:10.5812/ijem.23542]
31. Zhu L, Luo X, Jin Z. Effect Of Resveratrol On Serum And Liver Lipid Profile And Antioxidant Activity In Hyperlipidemia Rats. Asian Austral J Anim Sci 2008; 21(6): 890-5. [DOI:10.5713/ajas.2008.70638]
32. Dallak MM, Mikhailidis DP, Haidara MA, et al. Oxidative Stress As A Common Mediator For Apoptosis Induced-Cardiac Damage In Diabetic Rats. Open Cardiovasc Med J 2008; 2: 70-8. [DOI:10.2174/1874192400802010070]
33. Alabdan MA. Silymarin Ameliorates Metabolic Risk Factors And Protects Against Cardiac Apoptosis In Streptozotocin-Induced Diabetic Rats. Biomed Biotechnol 2015; 3(2): 20-7.
34. Thangasamy G, Pari L, Ellappan P, et al. Effect Of Pterostilbene On Cardiac Oxidative Stress On High-Fat Diet-Fed And Streptozotocin-Induced Type 2 Diabetic Mice. Asian J Pharm Pharmacol 2019; 5(4): 827-33. [DOI:10.31024/ajpp.2019.5.4.25]
35. Bousette N, Giaid A. Urotensin-II And Cardiovascular Diseases. Curr Hypertens Rep 2006; 8(6): 479-83. [DOI:10.1007/s11906-006-0026-7]
36. Leprince J, Chatenet D, Dubessy C, et al. Structure-Activity Relationships Of Urotensin II And URP. Peptides 2008; 29(5): 658-73. [DOI:10.1016/j.peptides.2007.08.014]
37. Cheng X, Zhang J, Chen Z. Effects Of Total Flavone From Rhododendron Simsii Planch. Flower On Postischemic Cardiac Dysfunction And Cardiac Remodeling In Rats. Evid-Based Compl Alt Med 2017; 2017: 9. [DOI:10.1155/2017/5389272]
38. Movahed A. Beneficial Effects Of Resveratrol, Present In Grapes In The Prevention And Treatment Of Heart Disease And Failure. Iran South Med J 2015; 18(1): 183-99. (Persian)
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |